Name: Tinlarebant (LBS-008) in Stargardt disease type 1: Effects of other drugs on Tinlarebant
Published: 2026-09-14T15:39:06-04:00

Product information and disease description Product description Product information Drug/Drug, drug/disease interactions

Effects of other drugs on Tinlarebant

3 evidence topics · 1 source

Pharmacokinetics and drug interactions: coadministration

Coadministration	“Cmax ratio”	“AUCinf ratio”
“omeprazole”	“1.16”	“1.03”
“itraconazole”	“1.29”	“2.42”
“Rifampin”	“0.53”	“0.19”

Publication recommendation concerning CYP3A inducers: not approved labeling

“contraindicated with strong CYP3A inducers” (opens the source at this quote in a new tab)

Investigator conclusion on coadministration and food

“These data show that the pharmacokinetics of tinlarebant is not significantly altered by gastric acid suppression or food.” (opens the source at this quote in a new tab)
“Dosing patients with tinlarebant and strong CYP3A inhibitors concurrently is unlikely to compromise safety based on its pharmacokinetic–pharmacodynamic relationships, but tinlarebant should be contraindicated with strong CYP3A inducers due to the risk of treatment failure.” (opens the source at this quote in a new tab)
“No unexpected safety signals occurred and tinlarebant was well tolerated in all participants.” (opens the source at this quote in a new tab)